Mizuho lowered the firm’s price target on Elevance Health (ELV) to $400 from $420 and keeps an Outperform rating on the shares. The firm reduced 2026 and 2027 earnings estimates to reflect additional headwinds in Carelon related to the expected regulatory driven membership changes. The firm assumes Elevance faces membership pressure in its Medicaid, Medicare Advantage and the health insurance exchange businesses due to the potential expiration of the enhanced advanced premium tax credits.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Enrollees of ACA plans learn of hefty premium increases, WSJ reports
- Elevance Health price target raised to $394 from $384 at JPMorgan
- Elevance Health price target raised to $380 from $330 at TD Cowen
- Elevance Health: Strategic Outlook and EPS Growth Support Buy Rating
- Elevance Health price target lowered to $385 from $395 at Barclays